(-)-Epigallocatechin-3-gallate (EGCG) sensitizes melanoma cells to interferon induced growth inhibition in a mouse model of human melanoma

Cell Cycle

Volumn 8, Issue 13, 2009, Pages 2057-2063

  Nihal, Minakshi ^a   Ahsan, Haseeb ^a   Siddiqui, Imtiaz A ^a   Mukhtar, Hasan ^a   Ahmad, Nihal ^a   Wood, Gary S ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Apoptosis; Cell cycle; Chemoprevention; Green tea; Interferon; Melanoma

Indexed keywords

CYCLINE; EPIGALLOCATECHIN GALLATE; FAS ANTIGEN; FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; SYNAPTOTAGMIN I;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; COLONY FORMATION; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; NUDE MOUSE; TUMOR GROWTH;

MUS MUSCULUS;

EID: 67650531883     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.13.8862     Document Type: Article

References (31)

1. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 2006; 20:2149-2182 (Pubitemid 44244518)
2. Demierre MF. Epidemiology and prevention of cutaneous melanoma. Curr Treat Options Oncol 2006; 7:181-186
3. Sharpless E, Chin L. The INK4a/ARF locus and melanoma. Oncogene 2003; 22:3092-3098
4. Ivanov VN, Bhoumik A, Ronai Z. Death receptors and melanoma resistance to apoptosis. Oncogene 2003; 22:3152-3161 (Pubitemid 36713767)
5. Dhomen N, Marais R. New insight into BRAF mutations in cancer. Curr Opin Genet Dev 2007; 17:31-39 (Pubitemid 46109299)
6. Rieger PT. Interferon-alpha: a clinical update. Cancer Pract 1995; 3:356-365
7. Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G. Side effects of interferonalpha therapy. Pharm World Sci 2005; 27:423-431
8. Meyskens FL Jr, Farmer PJ, Yang S, Anton-Culver H. New perspectives on melanoma pathogenesis and chemoprevention. Recent Results Cancer Res 2007; 174:191-195
9. Adhami VM, Mukhtar H. Anti-oxidants from green tea and pomegranate for chemoprevention of prostate cancer. Mol Biotechnol 2007; 37:52-57 (Pubitemid 350135905)
10. Khan N, Afaq F, Mukhtar H. Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid Redox Signal 2008; 10:475-510.
11. Valcic S, Timmermann BN, Alberts DS, Wachter GA, Krutzsch M, Wymer J, et al. Inhibitory effect of six green tea catechins and caffeine on the growth of four selected human tumor cell lines. Anticancer Drugs 1996; 7:461-468 (Pubitemid 26249199)
12. 2 cell proliferation and induces apoptosis through p53-dependent and Fas-mediated pathways. J Biomed Sci 2003; 10:219-227
13. Mukhtar H, Agarwal R. Skin cancer chemoprevention. J Investig Dermatol Symp Proc 1996; 1:209-214
14. Nihal M, Ahmad N, Mukhtar H, Wood GS. Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma. Int J Cancer 2005; 114:513-521 (Pubitemid 40349609)
15. Khan N, Afaq F, Saleem M, Ahmad N, Mukhtar H. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res 2006; 66:2500-2505
16. Amiri KI, Richmond A. Role of nuclear factor-kappaB in melanoma. Cancer Metastasis Rev 2005; 24:301-313
17. Ianaro A, Tersigni M, Belardo G, Di Martino S, Napolitano M, Palmieri G, et al. NEMO-binding domain peptide inhibits proliferation of human melanoma cells. Cancer Lett 2009; 274:331-336
18. Ross MJ, Martinka S, D'Agati VD, Bruggeman LA. NFkappaB regulates Fas-mediated apoptosis in HIV-associated nephropathy. J Am Soc Nephrol 2005; 16:2403-2411 (Pubitemid 41725058)
19. Warbrick E. The puzzle of PCNA's many partners. Bioessays 2000; 22:997-1006.
20. Eberle J, Fecker LF, Hossini AM, Kurbanov BM, Fechner H. Apoptosis pathways and oncolytic adenoviral vectors: promising targets and tools to overcome therapy resistance of malignant melanoma. Exp Dermatol 2008; 17:1-11. (Pubitemid 350269205)
21. Hussein MR, Haemel AK, Wood GS. Apoptosis and melanoma: molecular mechanisms. J Pathol 2003; 199:275-288
22. O'Brien DI, Nally K, Kelly RG, O'Connor TM, Shanahan F, O'Connell J. Targeting the Fas/Fas ligand pathway in cancer. Expert Opin Ther Targets 2005; 9:1031-1044 (Pubitemid 41488838)
23. Kamei T, Inui M, Nakase M, Nakamura S, Okumura K, Hiramoto K, Tagawa T. Experimental therapy using interferon-gamma and anti-Fas antibody against oral malignant melanoma cells. Melanoma Res 2005; 15:393-400. (Pubitemid 41558949)
24. Ekmekcioglu SMJ, Udtha M, Chada S, Grimm EA. Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/ IL-24. Cytokine 2008; 43:34-44.
25. Hayakawa S, Saeki K, Sazuka M, Suzuki Y, Shoji Y, Ohta T, et al. Apoptosis induction by epigallocatechin gallate involves its binding to Fas. Biochem Biophys Res Commun 2001; 285:1102-1106 (Pubitemid 32912894)
26. Sun XF, Zhang H. NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol Histopathol 2007; 22:1387-1398 (Pubitemid 47470331)
27. Ueda Y, Su Y, Richmond A. CCAAT displacement protein regulates nuclear factor-kappabeta-mediated chemokine transcription in melanoma cells. Melanoma Res 2007; 17:91-103. (Pubitemid 46673902)
28. Yang J, Amiri KI, Burke JR, Schmid JA, Richmond A. BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clin Cancer Res 2006; 12:950-960 (Pubitemid 43259878)
29. Erb P, Ji J, Kump E, Mielgo A, Wernli M. Apoptosis and pathogenesis of melanoma and nonmelanoma skin cancer. Adv Exp Med Biol 2008; 624:283-295
30. Ueda Y, Richmond A. NFkappaB activation in melanoma. Pigment Cell Res 2006; 19:112-124
31. Shammas MA, Neri P, Koley H, Batchu RB, Bertheau RC, Munshi V, et al. Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood 2006; 108:2804-2810 (Pubitemid 44777019)